Craig-Hallum Initiates Coverage On Ironwood Pharmaceuticals with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker has initiated coverage on Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy rating and set a price target of $21.
January 17, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ironwood Pharmaceuticals received a Buy rating from Craig-Hallum with a price target of $21, indicating a positive outlook from the analyst.
Analyst ratings, especially initiations of coverage with a Buy rating, can have a significant positive impact on a stock's price in the short term as it may lead to increased investor interest and confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100